Wilms’ tumor gene 1 is an independent prognostic factor for pediatric acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation

Table 2 Multivariate analyses for 2-year outcomes in patients without preemptive interventions (n = 96)

Variables	HR (95% CI)	P value
Relapse
Cytogenetics and molecular abnormalities
Intermediate	1.00
Unfavorable	3.41 (1.08–10.81)	0.037^*
Disease status before allo-HSCT
CR1	1.00
CR2	2.03 (0.39–10.43)	0.398
NR	114.16 (13.86–940.41)	< 0.001^*
MRD status after allo-HSCT
MRD-	1.00
WT1+ alone	6.15 (1.62–23.33)	0.008^*
MRDco+	14.70 (3.63–59.58)	< 0.001^*
DFS
Cytogenetics and molecular abnormalities
Intermediate	1.00
Unfavorable	2.88 (1.15–7.20)	0.024^*
Disease status before allo-HSCT
CR1	1.00
CR2	1.11 (0.24–5.04)	0.896
NR	33.06 (5.94–184.00)	< 0.001^*
MRD status after allo-HSCT
MRD-	1.00
WT1+ alone	2.97 (1.05–8.46)	0.041^*
MRDco+	6.37 (1.94–20.99)	0.002^*
OS
Cytogenetics and molecular abnormalities
Intermediate	1.00
Unfavorable	2.90 (1.10–7.66)	0.031^*
Disease status before allo-HSCT
CR1	1.00
CR2	0.47 (0.06–3.66)	0.472
NR	14.97 (2.95–76.02)	0.001^*
MRD status after allo-HSCT
MRD-	1.00
WT1+ alone	1.62 (0.49–5.42)	0.433
MRDco+	7.13 (2.11–24.07)	0.002^*

CR Complete remission, NR No remission, MRD- MRD negativity, WT1+ alone WT1 positivity alone, MRDco+ Combined MRD positivity, DFS Disease-free survival, OS Overall survival, HR Hazard ratio, CI Confidence interval
* means P < 0.05

ISSN: 1471-2407